BioSpace News Archive

The last few weeks have seen a flurry of filings for initial public offerings by biotech companies. Here’s a look.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

In a conference call on Wednesday, Biogen CEO Michel Vounatsos outlined the company’s plans for commercial distribution of Aduhelm.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, congratulates Hannah Valantine, MD on her State of the Art Lecture at the 2021 American Transplant Congress about the importance of equity in transplantation and genomic solutions to improve inclusivity.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced that company management will participate in the following upcoming investor conferences

International Expert Opinion and Implementation Guidance outlines Ketamine and Esketamine treatment parameters setting the standard for the clinical implementation of these rapid-acting treatments in treatment resistant depression

Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer.

NanOlogy, LLC, a clinical-stage oncology company, announced that additional data from its Phase 2 dose-rising and expansion clinical trial of intracystic NanoPac® for mucinous cystic neoplasms of the pancreas were presented via poster by Somashekar Krishna, MD, MPH of The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center during Digestive Disease Week held virtually from May 21-23, 2021.

Kojin Therapeutics Inc., the leading company developing new targeted therapeutics based on cell state and ferroptosis biology, launched with a $60 million Series A led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital, with participation from Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices.

OpGen, Inc. announced that its subsidiary Ares Genetics, which strives to become a leader in bacterial genomics and the AI-powered prediction of antimicrobial resistance, is developing a culture-free, genomic assay for comprehensive AMR surveillance.